The first crystal structure of the neurotransmitter/sodium symporter homolog LeuT revealed an occluded binding pocket containing leucine and 2 Na ؉ ; later structures showed tricyclic antidepressants (TCAs) in an extracellular vestibule Ϸ11 Å above the bound leucine and 2 Na ؉ . We recently found this region to be a second binding (S2) site and that binding of substrate to this site triggers Na ؉ -coupled substrate symport. Here, we show a profound inhibitory effect of n-octyl-␤-D-glucopyranoside (OG), the detergent used for LeuT crystallization, on substrate binding to the S2 site. In parallel, we determined at 2.8 Å the structure of LeuT-E290S, a mutant that, like LeuT-WT, binds 2 substrate molecules. This structure was similar to that of WT and clearly revealed an OG molecule in the S2 site. We also observed electron density at the S2 site in LeuT-WT crystals, and this also was accounted for by an OG molecule in that site. Computational analyses, based on the available crystal structures of LeuT, indicated the nature of structural arrangements in the extracellular region of LeuT that differentiate the actions of substrates from inhibitors bound in the S2 site. We conclude that the current LeuT crystal structures, all of which have been solved in OG, represent functionally blocked forms of the transporter, whereas a substrate bound in the S2 site will promote a different state that is essential for Na ؉ -coupled symport.
The first crystal structure of the neurotransmitter/sodium symporter homolog LeuT revealed an occluded binding pocket containing leucine and 2 Na ؉ ; later structures showed tricyclic antidepressants (TCAs) in an extracellular vestibule Ϸ11 Å above the bound leucine and 2 Na ؉ . We recently found this region to be a second binding (S2) site and that binding of substrate to this site triggers Na ؉ -coupled substrate symport. Here, we show a profound inhibitory effect of n-octyl-␤-D-glucopyranoside (OG), the detergent used for LeuT crystallization, on substrate binding to the S2 site. In parallel, we determined at 2.8 Å the structure of LeuT-E290S, a mutant that, like LeuT-WT, binds 2 substrate molecules. This structure was similar to that of WT and clearly revealed an OG molecule in the S2 site. We also observed electron density at the S2 site in LeuT-WT crystals, and this also was accounted for by an OG molecule in that site. Computational analyses, based on the available crystal structures of LeuT, indicated the nature of structural arrangements in the extracellular region of LeuT that differentiate the actions of substrates from inhibitors bound in the S2 site. We conclude that the current LeuT crystal structures, all of which have been solved in OG, represent functionally blocked forms of the transporter, whereas a substrate bound in the S2 site will promote a different state that is essential for Na ؉ -coupled symport.
crystal ͉ molecular dynamics simulation ͉ neurotransmitter:sodium symport ͉ second substrate (S2)-binding site ͉ scintillation proximity binding assay E ukaryotic members of the neurotransmitter:sodium symporter (NSS) family, which include transporters for ␥-aminobutyric acid (GABA), dopamine, norepinephrine, and serotonin (GAT, DAT, NET, and SERT, respectively), terminate cellular signaling by recapturing released neurotransmitter (1) (2) (3) . These secondary active transporters enable the thermodynamically uphill transport of their respective substrates across the plasma membrane of the presynaptic neuron in a cotransport (symport) mechanism driven by the Na ϩ electrochemical gradient (4) (5) (6) . DAT is the primary target of psychostimulants such as amphetamine and cocaine (7) , whereas the tricyclic antidepressants (TCAs) and selective serotonin-reuptake inhibitors (SSRIs) target SERT and/or NET (8) . NSS dysfunction has been implicated in several neurological and psychiatric disorders, such as epilepsy (9) , depression (10), autism (11) , migraine (12) , and obsessive-compulsive disorder (OCD) (13) .
Despite a wealth of information regarding the physiological and functional properties of NSS, no direct structural data were available until 2005, when Gouaux and colleagues published the structure of LeuT, a prokaryotic NSS homolog (14) . In this high-resolution crystal structure, leucine and 2 Na ϩ are located in an occluded binding pocket formed by central conserved transmembrane segments. Additional LeuT crystal structures were determined in which TCAs [clomipramine, imipramine, and desipramine (15, 16) ] were cocrystallized in an extracellular vestibule of LeuT located Ϸ11 Å above the occluded binding pocket (hereafter referred to as the primary binding (S1) site). In these crystals, the S1 site was occupied by leucine and 2 Na ϩ , and the overall structure was nearly identical to that of the initial structure determined in the absence of inhibitors. We recently showed that part of this extracellular vestibule comprises a second substrate-binding (S2) site (see Fig. 1A for graphical presentation of the key structural elements of LeuT) (17) . Binding of substrate to the S2 site allosterically triggers inward release of Na ϩ and substrate from the S1 site, enabling Na ϩ -coupled substrate symport. However, occupation of the S2 site by a TCA, or abolishing substrate binding by mutations in the S2 site, i.e., by individually replacing Ile-111 or Leu-400 with Cys, impaired this transport mechanism (17) .
Importantly, all functional studies of LeuT have been carried out on material purified in the detergent n-dodecyl-␤-Dmaltopyranoside (DDM; hereafter referred to as LeuT DDM ) (14) (15) (16) (17) (18) , whereas the crystal structures have come from LeuT in n-octyl-␤-D-glucopyranoside (OG; referred to as LeuT OG ) (14) (15) (16) 18) . Here, we show that OG impairs the Na ϩ -coupled symport mechanism and demonstrate a specific inhibitory effect of OG on substrate binding to the S2 site. In addition, we have determined a crystal structure of a LeuT mutant that clearly reveals the presence of 1 molecule of OG bound at the S2 site. Computational analyses of the various forms of LeuT stabilized by different occupancies of the S1 and S2 sites, compared with the LeuT OG crystal structures (14) (15) (16) 18) , show a consistent pattern of structural arrangements associated with the binding of compounds that act as substrate-like symport effectors or as symport uncouplers with inhibitor properties (17) . We conclude that all current LeuT crystal structures represent functionally blocked states with inhibitors in the S2 site, whereas a substrate in that site promotes a different state that would be essential for the Na ϩ -coupled symport mechanism. These findings highlight that the available structural data must be used with care in the functional analysis and a need for other structures and other approaches to elucidate the molecular details underlying ioncoupled transport.
Results and Discussion
Effect of Detergent on LeuT Activity. We demonstrated previously that 1 molecule of LeuT-WT DDM can bind Ϸ2 molecules of Leu, whereas L400C DDM , which has a mutation in the S2 site that disrupts binding, binds Leu with a stoichiometry of Ϸ1 (17). Remarkably, 3 H-Leu binding (at 100 nM) to LeuT-WT OG was only 47 Ϯ 10% (n ϭ 4) of that observed for LeuT-WT DDM , whereas binding to LeuT-L400C OG was the same as to L400C DDM ( Fig. 1 B and C) . Consistent with our previous findings, 1 molecule of LeuT-WT DDM bound Ϸ2 molecules of Leu, whereas the S2-site mutant L400C DDM bound Ϸ1 (Fig. 1 D  and E) (17) . Also, both WT OG and L400C
OG had a binding stoichiometry of Ϸ1 [ Fig. 1 D and E and supporting information (SI) Fig. S1 ]. Despite the major impact of the detergent on the stoichiometry of Leu binding to LeuT 
Detergent and Inhibitor Exert Similar Effects on LeuT Function.
To assess the functional effect of OG in the S2 site, we tested whether LeuT-WT or -L400C can bind a second molecule of Leu in the S2 site when S1 is occupied. WT and L400C were incubated overnight in the presence of Na ϩ and 100 nM 3 H-Leu before diluting the samples in Na ϩ -containing buffer ( Fig. 2 A  and B) . For WT DDM , S2 dissociated but S1 remained trapped, as seen by a reduction of the total binding to Ϸ50%, consistent with the simultaneous binding of 2 substrates molecules in DDM (17) . In contrast, WT OG binding only reached Ϸ50% compared with WT DDM (Fig. 1B) , but bound Leu (S1) remained trapped upon dilution in Na ϩ -containing buffer, consistent with the binding of only a single substrate molecule in the S1 site in OG. Similarly, binding to L400C DDM and L400C OG reached only Ϸ50% of that achieved in the doubly substrate occupied WT DDM (Fig. 1B) ; the 1 Leu molecule (in the S1 site) remained trapped upon dilution in Na ϩ -containing buffer (Fig. 2B ). To test further the binding stoichiometries, increasing concentrations of 3 H-Leu were added to the samples after stably reaching the Ϸ50% 3 H-Leu binding plateau ( Fig. 2 A and B) . No increase in the total binding was observed for WT OG , L400C DDM , or L400C OG , which reflects the inability of the S2 site to bind Leu in the presence of OG and/or the S2-site mutation. In contrast, 3 H-Leu binding to WT DDM started at 50%, because of the occupancy of the S1 site by 3 H-Leu, and increased in a concentration-dependent manner ( Fig. 2 A) . Plotting the increase in the total binding ( Fig. 2C ) revealed a K D Leu of the S2 site of 23.1 Ϯ 5.8 nM (n ϭ 3). Thus, in the presence of DDM, WT Leu binds with high affinity to both S1 and S2 sites.
To overcome the experimental limitations of direct radioligand binding at very high 3 H-Leu concentrations to the S2 site in the presence of OG, the readout for Leu binding to the S2 site was based on S2-mediated release of trapped S1 in the absence of Na ϩ ( Fig. 3 A and B) . Diluting the sample from Na ϩ -containing buffer into Na ϩ -free buffer (mimicking low physiological intracellular Na ϩ concentrations) had no significant effect on the binding activity of LeuT-WT and -L400C in either detergent, i.e., Leu remained trapped in the S1 site (17) . However, in WT DDM , increasing the concentration of Leu from 10 to 250 nM caused rapid, complete release of bound 3 H-Leu from the S1 site (Fig. 3A) . Plotting the t 1/2 of release as a function of the Leu concentration gave an EC 50 Leu of 15.8 Ϯ 2.7 nM (Fig.  3C) , a concentration similar to the K D Leu at the S2 site as determined by direct radioligand binding (Fig. 2C) . In contrast, in WT OG 250 nM Leu failed to trigger release of trapped 3 H-Leu from the S1 site (Fig. 3A) . Complete release of S1 in WT OG was observed only with Leu concentrations of 100 mM and only after 4 days, consistent with greater than a millionfold reduction of the EC 50 Leu of the S2 site in the presence of OG. Binding of 2.5 mM Leu to L400C DDM was able to trigger complete release from S1 (17) with a t 1/2 of 15.5 Ϯ 2.3 min, reflecting a large effect of the mutation on the EC 50 Leu of the S2 site (for comparison, the t 1/2 of WT DDM was 1.3 Ϯ 0.1 min at the highest Leu concentration tested (250 nM); Fig. 3C ). In contrast, L400C OG showed essentially no release of S1, even in the presence of 100 mM Leu, suggesting that OG still binds to the disrupted S2 site in this mutant and impairs Leu binding much more than the mutation itself.
In testing the effects of other known S2-site binders, we found that addition of the TCA clomipramine (CMI) at 500 M, a concentration approximately twice the IC 50 for CMI inhibition of 3 H-Leu transport (15) , failed to trigger release of S1 (Fig. 3A) , even though it has been shown to bind to the S2 site (15, 16) (Fig.  S2 C and D) . Similarly, addition of 40 mM (Ϸ1.2 [wt/vol] %) OG, the concentration used for all LeuT crystallization assays, to LeuT-WT DDM did not trigger the release of bound 3 H-Leu from the S1 site. Furthermore, we assayed 100 nM 3 H-Leu binding to LeuT DDM in the presence of increasing concentrations of OG. Fig. 3D shows that OG dose dependently inhibits Ϸ50% of the 3 H-Leu binding with an IC 50 OG of 6.7 Ϯ 0.8 mM. Thus, the actions of OG are like those observed for TCA binding in the S2 site.
Identification of a Detergent Molecule in the Extracellular Vestibule.
Although we cannot rule out an indirect effect of OG on the S2 site, the similarity of its functional effect to that of TCAs suggested to us that OG might bind within the S2 site where it would directly compete with Leu. We serendipitously observed this to be the case in studying the chloride-dependent LeuT-E290S mutant (19) . Although LeuT-E290S has reduced apparent affinities for Na ϩ and Leu, like WT it exhibits a binding stoichiometry of Ϸ2 and Ϸ1 when assayed in DDM or OG, respectively (Fig. S1) .
The E290S mutant crystallized in a P2 1 crystal form with 2 molecules in the asymmetric unit and diffracted at 2.8 Å resolution (Fig. 4A and Table S1 ). Although diffracting at lower resolution than LeuT-WT crystals in the C2 form, the P2 1 form allowed for model refinement and a detailed analysis of bound ligands (Fig. 4) . It shows a structure of E290S, which is overall very similar to that of WT with an rmsd ϭ 0.49 Å for all C␣-atoms. The E290S mutation appeared from the electron density maps but despite the functional dependence on chloride no bound Cl Ϫ could be detected in this P2 1 crystal form. However, of particular interest to the present work is that the electron density we observed in the extracellular vestibule can be identified clearly as a bound OG molecule (Fig. 4 and Fig. S4 ). The glycoside head group is packed against the Asp-401 side chain, whereas the C8 aliphatic chain enters the proposed S2 site (17) , enclosed by a salt bridge formed between Arg-30 and Asp-404 and lined by the side chains of Leu-29, Tyr-107, Tyr-108, Ile-111, Phe-320, and Leu-400 (Fig. 4 C and D) .
This observation prompted us to analyze carefully LeuT-WT crystal structures. With the original aim of revealing leucine at the S2 site we had collected a 2.0-Å resolution dataset from C2 form crystals of LeuT-WT grown in the presence of 1 mM Leu (Fig. S2 A and B and Table S1 ). We combined this analysis with a revisit of the deposited data of LeuT crystallized in the absence of added leucine [PDB ID code 2A65 (14)]. We observed a similar residual density in the extracellular vestibule of both LeuT-WT structures (Fig. S2B , green and orange mesh, respectively), which is further corroborated by the difference Fourier map between these 2 datasets (F obs (1 mM Leu) Ϫ F obs (no Leu) ) showing no features. These observations indicate that in the C2 forms of WT crystals the S2 site is occupied by a similar entity, which is most likely not leucine. However, the OG molecule found in the P2 1 crystal form of the E290S mutant, by means of the C8 aliphatic tail, accounts well for the residual electron density in the C2 form WT structures (Fig. S3) . The glycoside head group exhibits greater disorder ( Fig. 4D and Fig. S3 ) with poor definition in the electron density map, which may explain why the site had escaped earlier attention. Refinement of the bound OG molecule in the C2 form further supports that only the C8 tail adopts a defined position, whereas the head group is disordered (Fig. S3 ).
Molecular Dynamics (MD) Simulations Suggest the Structural Arrangements That Determine the Mechanistic Role of the S2 Ligand.
The functional importance of these observations is underscored by our findings that different ligands binding in the S2 site can act as substrate-like symport effectors, or as symport uncouplers with inhibitor properties (17) . To obtain insight into the mechanistic origins of these differences in a structural context, we carried out MD simulations of LeuT with various ligands in the S2-binding site: substrates (Leu, Ala) (17, 20) , or inhibitors (CMI (15), OG), as well as for an unoccupied (U) S2 site to serve as a ''reference state'' for the comparisons. Starting from the 3 available crystal structures (i) WT-S1:Leu/S2:OG (Leu in S1 site and with OG inferred to be in the S2 site [PDB ID code 2A65 (14) ]; (ii) WT-S1:Leu/S2:CMI [PDB ID code 2Q6H (15)]; and (iii) E290S-S1:Leu/S2:OG, we carried out MD simulations for the following configurations: WT-S1:Leu/S2:OG, WT-S1:Leu/ S2:U, WT-S1:Leu/S2:Leu, WT-S1:Ala/S2:Ala, and E290S-S1:Leu/S2:U.
At the end of 50-ns MD runs for each configuration, the structures exhibited a number of different conformations of the extracellular-facing region of the transporter, depending on whether the S2 site was occupied by a ligand, and on the nature of the ligand. Comparisons with the original LeuT crystal structure (14) showed that a significant conformational variability involves the extracellular end of TM6 comprising residues 241 to 252 (TM6e). To quantify the structural rearrangements illustrated in Fig. 5 , we calculated and compared the angles between the axes of TM6e and the extracellular portion of TM3 (TM3e: residues 104-118) and TM10 (TM10e: residues 399-410); the latter segments were chosen because TM3e and TM10e contribute to the formation of the S2 site (15) (16) (17) . These 2 angles are denoted A 6e-3e and A 6e-10e , respectively, and the angle definition is given in Fig. 5E .
Remarkably, the original LeuT-WT crystal structure (PDB ID code 2A65, i.e., WT-S1:Leu/S2:unassigned OG), the LeuT-WT crystal structure with CMI (PDB ID code 2Q6H, WT-S1:Leu/ S2:CMI), the LeuT-E290S crystal structure (E290S-S1:Leu/ S2:OG), and our simulated structure of LeuT-WT with OG (MD-WT-S1:Leu/S2:OG) all have very similar values of the A 6e-10e angle (89.7°, 89.3°, 91.8°, and 90.6°, respectively). This similarity holds for the A 6e-3e angle as well (101.1°, 100.9°, 100.2°, and 98.9°). In contrast, the angle values calculated for the LeuT structure obtained from simulations in which the S2 site was occupied by the substrates Leu or Ala exhibited much smaller values of these angles: 85.9°/83.0°for A 6e-10e and 92.6°/92.2°for A 6e-3e. Our simulation of WT-S1:Leu/S2:U showed values 85.2°a nd 100.5°for the A 6e-10e and A 6e-3e angles, respectively, which reflects an orientation of TM6e that is intermediate between the substrate-bound and inhibitor-bound conformations, and consistent with the S2-apo state being a conformational intermediate that would differ from the original crystal structure. These TM6e rearrangements in TM6e related to the presence of various compounds in the S2 site are likely to be facilitated by the flexibility of the locally unwound region of TM6, which is only 1 helical turn away.
The clear structural grouping and internal consistency of our findings suggests (i) that the original crystal structure of LeuT (14) shows all of the properties of occupancy in the S2 site, most likely by OG, and (ii) that although substrates and inhibitors bind in the same S2 site, they produce distinct alterations of the structure as indicated by the distributions of A 6e-3e and A 6e-10e values from our simulations.
LeuT Structures and Leucine-Binding Sites S1 and S2 in Functional
Context. Taken together, our data show that OG and TCAs share mechanistic properties and functional effects, so that the LeuT structure in OG (the structures determined in this study and that of ref. 14) represents, in fact, an inhibitor-bound structure, accounting for its near identity to the TCA-bound structures (Fig. S2 C and D) (15, 16) .
In the absence of the profound inhibitory effects of OG, substrate binding to both the S1 and S2 sites is of high affinity, and S2 serves to couple the sodium gradient to intracellular release of S1, thereby prompting us to refer to a substrate in the 1 LeuT-E290S structure. The P21 structure of LeuT-E290S contains 2 molecules in the asymmetric unit (green and yellow cartoon representation). All OG molecules identified in the structure are highlighted with purple and red spheres (carbon and oxygen, respectively) and the location of leucine at the S1 site is shown with blue and red spheres (and magenta spheres for Na ϩ ). OG molecules bound at the S2 site are labeled with blue asterisks. (B) Schematic representation of a monomer of the LeuT-E290S structure is shown in yellow with the identified OG at the S2 site and the leucine-bound S1 site represented by spheres. (C) The unbiased F obs Ϫ F calc difference map calculated at 30-to 2.8-Å resolution for the P21 form of the LeuT-E290S structure before any modeling of the OG ligand at the S2 site. Other than the most exposed part of the glycoside head group, the OG model provides a snug fit to the residual density at the S2 site. (D) Electron density map of the S2 site in the LeuT-E290S structure. The final A-weighted 2Fobs-Fcalc electron density map displayed at 1 contour level around the final model. The LeuT model is represented by stick representation with carbon atoms in yellow, nitrogen in blue, and oxygen in red. The OG model is displayed in a color-ramp according to the B-factor range 40 -160 Å 2 (green to red) highlighting a poor order of the glycoside head group. S2 site as a symport effector (17) . In contrast, an inhibitor at the S2 site blocks substrate binding to this site, and, unlike a substrate molecule, does not couple inward release of S1 to the sodium gradient, thereby acting as a symport uncoupler. Our results provide a structural context for the functional distinction between symport effectors and uncouplers in a manner not discernable directly from the currently available crystal structures of LeuT.
While this manuscript was being considered for publication, LeuT structures were published with a variety of substrates in the S1 site (18) . Substrate was not found in the S2 site of any of several S1-bound LeuT cocrystals, which led the authors to conclude that the S2 site represents a low-affinity, transiently occupied site for substrates as they move from the extracellular vestibule to the S1 site. This conclusion fails to account for the available data, most importantly: (i) a transient occupation of the S2 site would not be detectable in equilibrium binding experiments, whereas, in the present article, we further validate a previously reported finding of binding stoichiometry of 2 molecules Leu per molecule of LeuT-WT DDM (17) , (ii) the K D Leu for binding of Leu to the S1 and S2 sites in LeuT-WT DDM is nearly identical (Figs. 1D, 2C , and 3C and Fig. S1 ), arguing directly against low-affinity substrate binding to either site, and (iii) impairing substrate binding to the S2 site, either by mutations or binding of TCAs (17) or OG, inhibits the Na ϩ -coupled substrate symport mechanism. Interestingly, it was shown recently that noncharged detergents, including OG, are not inert compounds, because they bind to the efflux-transporter P-glycoprotein and modulate drug effects with specificities overlapping those of substrates (21) . Also, OG was reported to inhibit the renal Na ϩ /glucose transporter in a competitive fashion with an IC 50 OG of ϳ10 M (22) . Although this transporter exhibits a high specificity for the glucoside head group of the detergent, the length of the aliphatic chain was found to play a significant role in the inhibitory effect; inhibition of sugar transport Ն 90% was observed with alkyl side chains ranging from 8-11 carbon atoms in length. It is tempting to speculate that whereas the C8 aliphatic side chain of OG can fit in the S2 binding site the longer side chain of DDM (C12) cannot.
Thus, the OG present in the crystallization conditions of all LeuT structures so far blocks substrate binding to the S2 site and thus predetermines a functionally inhibited state (Fig. S4) . Other crystal structures of apo, S2-apo, and double-substrate-bound transporters, with reduced interference of applied detergents, as well as the conjoint application of other approaches, will be required to elucidate further the molecular details underlying ion-coupled transport in LeuT and thereby help in the discovery of the general mechanistic principles of the NSS transporter family.
Materials and Methods
Protein Expression, Purification, and Crystallization. For functional studies LeuT-WT, -L400C, and -E290S were produced in E. coli C41(DE3) harboring pQO18 (or its derivatives carrying given mutations) (17, 19, 23) , whereas for the crystallization of LeuT-WT and -E290S, the corresponding alleles were incorporated in pET16b derivatives (14) and expressed in Escherichia coli C41(DE3), as described (17) . LeuT variants were purified by immobilized metal (Ni 2ϩ ) affinity chromatography as described (17) with the exception of using Ni 2ϩ Sepharose 6 FastFlow (GE Healthcare) instead of PrepEase HighYield Histidine purification resin (Affymetrix) and adding 10 M Leu to all chromatography buffers for the crystallization. Purified protein of pET16b-derived LeuT-variants (containing a thrombin site before the octa-histidine tag) was treated with 10 units of thrombin (Calbiochem) at 4°C overnight. Before HPLC-mediated size-exclusion chromatography (Shodex Protein-KW803 column) performed in buffer composed of 20 mM Tris/Mes (pH 8.0)/100 mM NaCl, 1 mM TCEP and either 0.05 [wt/vol] % (1 mM) n-dodecyl-␤-D-maltopyranoside (functional studies) or 1.17 [wt/vol] % (40 mM) n-octyl-␤-D-glucopyranoside (functional studies and crystallization), the protein was concentrated to Ϸ5 mg/mL (Vivaspin6, MWCO 50,000). 10 M Leu was added to the sizeexclusion buffer of LeuT-WT subsequently used for crystallization. Whereas the pooled protein fractions for functional studies were assayed (24) and frozen until further use, protein used for crystallization was concentrated (Vivaspin500, MWCO 50,000) to Ϸ7 mg/mL (Nanodrop; Thermo Scientific) and immediately used for crystallization setup. Crystals were obtained in a crystallization buffer with 0.1-0.2 M NaCl, 16 -23% (wt/vol) PEG 550 MME, and 0.1 M Hepes (pH 7.0) and cryoprotected by gradually increasing the PEG concentration in the drop to 27-30%. The crystals were flash-cooled in liquid nitrogen, and data were collected at I911-2 MaxLab, Lund, Sweden and at X06SA Synchrotron Light Source, Villigen, Switzerland. The structures were determined by molecular replacement using the program Phaser (25) and the LeuT-WT structure (PDB ID code 2A65) as a search model. The structures were built with the molecular graphics program Coot (26) and refinement of the model performed with the Phenix package (27) . Fobs Ϫ Fobs difference Fourier maps were calculated by using model-derived phases.
Scintillation Proximity-Based Binding Studies. Binding of 3 H-leucine (140 Ci/ mmol; Moravek) to purified LeuT-variants was performed by means of the The conformational space explored during MD simulations by MD-WT-S1:Leu/S2:OG (purple-blue for protein backbone, with OG in magenta) and MD-WT-S1:Leu/S2:U (green) differs most at the extracellular portion of TM6 (TM6e). For comparison, the traces from these simulations are superimposed on the crystal structures WT-S1:Leu/S2:OG (cyan; PDB ID code 2A65) and WT-S1:Leu/S2:CMI (pink; PDB ID code 2Q6H). The superposition is based on the C␣ atoms of TM3 and TM8, which differ least among these structures. (B) Superposition of MD-E290S-S1:Leu/S2:U (orange), MD-WT-S1:Leu/S2:U (green), and the crystal structure of E290S-S1:Leu/S2:OG (magenta), viewed from the same angle and using the same superposition scheme as in A. (C) Superposition of WT-LeuT structures. Note that with reference to TM6e of MD-WT-S1:Leu/S2:U, the TM6e of MD-WT-S1:Ala/S2:Ala (yellow), which has a substrate in the S2 site, moves in a direction opposite to that seen for this TM portion in the crystal structure WT-S1:Leu/S2:OG (cyan; PDB ID code 2A65). The simulation results are shown as traces in A and as average structures in B and C. (D) Top view of the superposition of MD-WT-S1:Ala/S2:Ala and the crystal structure WT-S1:Leu/S2:OG, WT-S1:Leu/S2:CMI, and E290S-S1:Leu/S2:OG, with the same color coding as defined in A-C. (E) Definition of the inter-TM angles, illustrated for A 6e-10e. The cylinders represent the identified TM segments in the exact configurations and color coding shown in D. Note that the reference position (cyan) is defined by TM3e and TM10e, and the position of TM6e is shown for each of the compared structures. The usual definition of the angle between noncoplanar segments is illustrated for the WT-S1:Leu/S2:OG (cyan) structure. Line a is the perpendicular connecting TM6e and TM10e, which are noncoplanar; line b is the projection of TM6e on the plane that is perpendicular to a and intersects with TM10e.
scintillation proximity assay (SPA) as described (17) with 25 ng of purified protein per assay in buffer composed of 20 mM Tris/Mes (pH 8.0)/100 mM NaCl, 1 mM TCEP and either 0.05% n-dodecyl-␤-D-maltopyranoside or 1.17% noctyl-␤-D-glucopyranoside, unless indicated otherwise. All experiments were repeated at least in duplicate, with triplicate determination of all individual data points. Kinetic constants were obtained by subjecting the data of independent experiments to global fitting in Prism or SigmaPlot and shown with or without the SEM of the fit.
MD Simulations. MD simulations were performed as described (17) . All of the MD simulations were run for 50 ns with NAMD (28) by using the same procedures and explicit solvent models as we described recently (17) . Parameters for OG are based on the CHARMM carbohydrate solution force field (CSFF) (29) in combination with those of lipid tails from CHARMM27 force field (30) . The initial pose of OG in the S2 site for the WT-S1:Leu/S2:OG simulation is taken from that of the crystal structure E290S-S1:Leu/S2:OG, along with the corresponding rotamer change of the Arg-30 residue to fit OG in the cavity. The E290S-S1:Leu/S2:U construct was obtained from the simulated WT-S1:Leu/ S2:U model (12-ns point of the MD trajectory) in which the E290S mutation was introduced and followed by energy minimization. Molecular graphics were done with the PyMOL package (31) .
